“is it 2022 or 2023?”
Well done Wingmann for sowing that seed! You are an apologist for JF!
Just to remind you, again, that JF stated at last years AGM that
“Our expectations is for all three of these phase *3 products to be completing and reading out in calendar year 2022
And I would expect that the first half would include dep docetaxel and the prostate component of dep cabazitaxel”
How can anyone believe anything she says? I certainly don’t.
Starpharma after 22 years, page-32
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
-0.005(4.76%) |
Mkt cap ! $41.23M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 10.0¢ | $3.333K | 32.72K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 34430 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 115551 | 4 |
View Market Depth
| Last trade - 13.58pm 12/07/2024 (20 minute delay) ? |
| SPL (ASX) Chart |